As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial
Aims To Challenge Keytruda Dominance
One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.
